Skip to content

The Impact of Insomnia on Pain in HIV

The Impact of Insomnia on Pain, Physical Function, and Inflammation in HIV

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04298658
Acronym
HIPPI
Enrollment
171
Registered
2020-03-06
Start date
2020-01-01
Completion date
2025-07-31
Last updated
2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV, Insomnia

Brief summary

The overall objective of this application is to investigate the impact of insomnia on pain, physical functioning, and inflammation in people living with HIV. The two aims of this study to determine 1) whether insomnia promotes increased sensitivity and inflammatory reactivity to pain stimuli, and 2) if weekly fluctuations in insomnia burden drive changes in inflammation, pain severity, and physical functioning in people living with HIV. This research could help confirm insomnia as a therapeutic target for the suppression of pain and inflammation in people living with HIV.

Detailed description

Experimental session 1 Resting Blood Pressure and Body Mass Index will be assessed. Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test. Study staff will administer the Structured Interview for Sleep Disorders and administer the Rapid Estimation of Adult Literacy Measure-Short Form (REALM-SF) to determine health literacy. The night of Experimental Session 1 participant will be using a Resmed ApneaLink Air device (Resmed, San Diego, CA), to identify apnea and hypopnea and calculate an apnea hypopnea index. Between Experimental Session 1 and Experimental Session 2 Sleep assessment: Sleep data will be collected by participants in their own homes using objective and subjective measures of their sleep. Participant instructions for how to collect and record their own sleep data will be provided at the end of study session 1. Participant will be provided with a watch-like device to wear on wrist for 7 consecutive days and nights. This watch measures physical activity and sleep. Experimental Session 2 Resting Blood Pressure and temperature will be assessed. A sample of urine will be taken to test for illicit substances that might affect the study's results. Experimental session 2 will take place in the Center for Clinical and Translational Science (CCTS) Clinical Research Unit (CRU). A clinical Research Unit (CRU) nurse will place an intravenous (IV) cannula (small plastic tube) in the arm using a needle to draw blood at the beginning of the session and then an additional four times across the study for a total of five blood draws. Participants will complete multiple questionnaires to measure health, and experience with insomnia, pain, mood and emotions, experiences with stigma and discrimination, and how participant thinks and feels about things. All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 3-4 hours. Blood will be processed and stored and then used to measure inflammation. Weekly Follow-up Sessions Participants will then complete a battery of ecologically valid movement tasks that include: 1) Performance Battery (SPPB) which includes sitting in a chair, transitioning to a standing position, balancing tests and gait speed, and the Timed Up and Go test (TUG). A clinical Research Unit (CRU) nurse will draw a quick sample of approximately 20 milliliters from the participants arm using a butterfly needle so that CRU nurse can collect blood during the beginning of each visit.

Interventions

DIAGNOSTIC_TESTStructured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised

Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)

DIAGNOSTIC_TESTResmed ApneaLink Air device (Resmed, San Diego, CA).

Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).

All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.

DIAGNOSTIC_TESTOraQuick Advance Rapid HIV 1/2 Swab test

Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.

DIAGNOSTIC_TESTCluster of Differentiation 4 (CD4) and Viral load

Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

HIV with Insomnia * Confirmed HIV diagnosis * currently a patient in the University of Alabama (UAB) 1917 HIV Clinic. * must be currently receiving stable antiretroviral therapy (ART). * Meets the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for insomnia including sleep difficulty. HIV Without Insomnia * Confirmed HIV diagnosis * currently a patient in the University of Alabama (UAB) 1917 HIV Clinic. * must be currently receiving stable antiretroviral therapy (ART). * Does not meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for insomnia including sleep difficulty. Non HIV with Insomnia * Confirmed Non HIV diagnosis and currently not a patient in the UAB 1917 HIV Clinic. * Meets DSM-5 diagnostic criteria for insomnia including sleep difficulty. Non HIV Without Insomnia * Confirmed Non HIV diagnosis and currently not a patient in the UAB 1917 HIV Clinic. * Does not meets DSM-5 diagnostic criteria for insomnia including sleep difficulty.

Exclusion criteria

* concurrent medical conditions that could confound * interpretation of sleep * pain * inflammatory issues or coexisting diseases * Systemic rheumatic disease/condition * uncontrolled hypertension (i.e., BP \> 150/95) * circulatory disorders (e.g., Reynaud's disease) * history of heart disease or cardiac events * history of cancer * asthma AND use of an inhaler * history of seizures * history of stroke or other neurological disorder * pregnancy * core body temperature \> 100 degrees Fahrenheit as this could indicate acute infection with fever; (k) * unwilling to provide blood for this study * non-English speaking * recent injury or surgical procedure within past 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Weekly Caffeine DiariesBaseline up to 8 weeksA caffeine dairy including different types of caffeine generally available for the participants to record their daily caffeine consumption of for seven days.
Pro-Inflammatory markersBaseline up to 8 weeksTNF-a, IL-6, IL-12, IL-18, C-reactive protein, sCD14/163, D-dimer and IFN-gamma assays will be performed on the blood to identify levels of pro-inflammatory markers.
Anti-Inflammatory markersBaseline up to 8 weeksIFN-a, TGF-B, IL4, IL-10 and IL-13 assays will be performed on the blood to identify levels of anti-inflammatory markers.
Oxidative Stress markersBaseline up to 8 weeksMitochondrial DNA damage, Damage associated molecular patterns (DAMPS) and Cortisolassays will be performed on the blood to identify levels of anti-inflammatory markers.
Pain thresholdBaseline up to 1 weekPain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation first becomes painful
Pain toleranceBaseline up to 1 weekPain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are no longer willing to tolerate the painful sensation.
Punctate StimuliBaseline up to 1 weekMonofilament touch test refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Participants will be asked to rate their pain after being stimulated either once or ten times with vonfrey filament, or until they can no longer tolerate the painful sensation.
Temporal summation of painBaseline up to 1 weekTemporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. A series of 5 heat pulses will be repeated every two seconds starting at a baseline temperature of 40 and participants will be asked to rate how painful each peak of the pulse feels to them using a pain rating of 0-100 (0 no pain at all to 100 the most intense pain imaginable). These heat pulses will be repeated randomly at three different temperatures peaking at 44, 46, and 48 degrees in Celsius.
Conditioned pain modulationBaseline up to 1 weekA routinely used quantitative sensory testing protocol for the measurement of endogenous pain inhibition, which refers to the reduction in pain from one stimulus (the test stimulus) produced by the application of a second pain stimulus (the conditioning stimulus). The conditioning stimulus will be the cold pressor task (Thermo Scientific) applied to the non-dominant hand. For this procedure the cold water will be maintained at 10C and participants will keep their hand immersed for 60 seconds. Upon removal of the hand, a mechanical pressure stimulus will be applied. The pressure stimulus used is a handheld, digital pressure algometer (Algomed, Medoc, Ramat Yishai, Israel) to assess pressure pain applied to the dominant forearm and ipsilateral trapezius by gradually increasing pressure at a rate of 30 kiloPascals (maximum 1000 kiloPascals) per second until participants indicate when the increasing pressure first becomes painful by pressing a button on a device they will be holding.
Actigraph Sleep MeasurementBaseline up to 8 weeksA light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light.
Weekly Sleep DiariesBaseline up to 8 weeksA sleep diary including 15 daily questions will be filled out every day for seven days including questions about a participants nightly sleep experiences.

Secondary

MeasureTime frameDescription
Short Physical Performance BatteryWeek 2 up to 8 weeksThe SPPB consists of 3 individual sub-tests - standing balance (participants are asked to stand in 3 easy stances for 10 seconds), 4-meter gait speed (participants are asked to walk a steady pace in a straight line for 4-meters) and 5-repetition sit-to-stand (particpants are asked to stand up and sit back down in a stable chair up to 5 times). All 3 are simple and quick to perform in the outpatient setting and require only limited equipment; participants are asked to rate difficulty 0-100 (0 no difficulty and 100 being the most difficult imaginable) and pain 0-100 (0 no pain and 100 being the most pain imaginable).

Other

MeasureTime frameDescription
Drug Abuse Screening Test (DAST10)Baseline up to 1 weekThis drug screening asks questions related to the consequences of drug abuse and the problems associated with it.
State Trait Anxiety InventoryBaseline up to 1 weekThis psychological questionnaire aims to measure the intensity of anxiety. It seeks to separate the state anxiety (temporary) from trait anxiety (general), as well as general anxiety and depressive feelings.
Penn State Cigarette Dependence Index - CigarettesBaseline up to 1 weekSeeks to measure the level of addiction/dependence on smoking cigarettes.
Penn State Cigarette Dependence Index - EcigarettesBaseline up to 1 weekSeeks to measure the level of addiction/dependence on smoking electronic cigarettes.
Alcohol Use Disorders Identification Test - C (AUDIT)Baseline up to 1 weekThis questionnaire assesses alcohol consumption as well as related problems and behaviors.
Alcohol Smoking and Substance Involvement Screening Test (ASSIST)Baseline up to 1 weekThis questionnaire detects and measures substance abuse, alcohol, and smoking as well as related problems. It aims to detect the risky behavior related to each.
Anger PROMISBaseline up to 1 weekThis questionnaire measures emotions, primarily anger, relevant to the past 7 days.
Timed Up and Go (TUG) TaskWeek 2 up to 8 weeksThe Timed Up and Go test (TUG) is a commonly used screening tool to assist clinicians to identify patients at risk of falling. Participants are asked to start in a sitting position in a chair, stand up and walk approximately 3 meters before turning to return to the chair at a steady, straight pace. The outcome will be measured with a stopwatch, then rating difficulty 0-100 (0 no difficulty and 100 being the most difficult imaginable) and pain 0-100 (0 no pain and 100 being the most pain imaginable).
Pain Catastrophizing Scale (PCS)Baseline up to 1 weekThis is a subjective look into how catastrophizing impacts an individual's pain. Specifically, it aims to measure catastrophic thinking related to pain they experience during the experimental session.
HIV Stigma MechanismsBaseline up to 1 weekThis questionnaire aims to see how an individual internalizes their experiences with HIV. Further, it asks about the negative feelings related and the beliefs associated with HIV.
Heightened Vigilance Scale (HVS)Baseline up to 1 weekMeasures the different ways people anticipate experiencing discrimination in their everyday life by asking them to rate 4 items that describe how they prepare to face day to day discrimination (scale 1-6; 1 almost every day, 6 never).
Experience of Discrimination (EOD)Baseline up to 1 weekThis scale evaluates each individual's experiences of discrimination. By providing a list of reasons a person may be discriminated against, it aims to see how each individual perceives their experiences.
Adverse Childhood Experiences (ACE)Baseline up to 1 weekThis questionnaire scores on a 10 point scale, and asks about childhood experiences in reference to abuse and neglect.
Lee Fatigue Scale (LFS)Baseline up to 1 weekThis 0-10 rating scale aims to assess fatigue and energy over time.
Perceived Stress Scale (PSS)Baseline up to 1 weekThis 14 -item self-report scale measures the degree to which an individual perceives the amount of stress in their lives.
Munich Chrono Type Questionnaires (MCTQ)BaselineConsisting of 19 questions, this is a self-reported scale that is used to assess the midpoint of everyday wake and sleep schedules, as well as assessing an individual's chronotypes.
Insomnia Severity Index (ISI)Baseline up to 8 weeksUsing a 5-point scale and 7 questions, the ISI has each participant subjectively measure their insomnia severity.
Demographics (DEMO)BaselineThis questionnaire better helps the investigators understand how each participant's financial, racial, social, etc. background. It ranges from general questions such as age and birthday, to socioeconomic questions such as work status and financial stability.
Center for Epidemiological Studies - Depression (CESD)Baseline up to 8 weeksBy specifically asking about the past week, this questionnaire seeks to gain a better understanding of each participant's state of mind in reference to depressive behaviors and/or feelings.
RU SatedBaseline up to 8 weeksSleep is a key aspect in an individual's everyday life. This questionnaire measures overall sleep quality in six different categories---Regularity, Sleep quality, alertness, timing, efficiency, and duration. This helps investigators understand a person's sleep efficacy.
Physical Health Questionnaire (PHQ-15)BaselineThe main goal of this questionnaire is to assess and individual's overall health status/condition. It asks questions about a person's physical well-being, and aims to identify any illnesses they may be suffering from.
Difficulties in Emotion Regulation Scale (DERS)BaselineThis questionnaire aims to subjectively measure the different emotions a person may be feeling, and how difficult it may be for a person to regulate those emotions.
Dysfunctional Beliefs and Attitudes about Sleep (DBAAS)BaselineThis questionnaire measures various sleep related attitudes and assesses beliefs about sleep that are related to insomnia.
Pain Interference and Intensity (PI-I)week 1 up to 7 weeksThis questionnaire seeks to understand how pain has an influence/impacts an individual's everyday life and activities, sleep, and mood in general.
Sorge 24 Hour Food RecordBaseline up to 1 weekTcord provides individuals with the space to write down what they've eaten in the past 24 hours, as well as what time, where they ate it, and about how much they think that they ate.
Sorge Dietary HabitsBaseline up to 1 weekThis questionnaire asks about a person's general diet and intake.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026